Elite Pharmaceuticals and Lannett terminate Vigabatrin agreement; marketing rights return to Elite

ELITE PHARMACEUTICALS INC /NV/

Joint termination of License, Supply and Distribution Agreement for Vigabatrin effective Nov 9, 2022.
All marketing rights for Vigabatrin revert to Elite Pharmaceuticals.
Agreement was with Lannett Company, Inc.; no further details on reason or financial impact.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ELITE PHARMACEUTICALS INC /NV/ terminated License, Supply and Distribution Agreement with Lannett Company, Inc. (effective 2022-11-09).

Action: termination
Agreement: license
Counterparty: Lannett Company, Inc.
Effective: 2022-11-09

Exact text from the filing

On November 9, 2022, Elite Pharmaceuticals Inc. (“Elite”) and Lannett Company, Inc. (“Lannett”) jointly terminated the License, Supply and Distribution Agreement for Vigabatrin effective as of November 9, 2022.

View on SEC.gov

Browse all material agreements →

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-22-031356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.